MapLight Therapeutics
MPLT | NASDAQ
$6.90
-$0.35 (-4.83%)
At close: Nov 16, 2026, 4:00 PM ET
$7.03
+$0.13 (+1.88%)
After-hours:
Nov 16, 2026, 4:40 PM ET
MapLight Therapeutics Company Profile
Company profile explainedCompany Profile
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Key Executives
| Name | Position |
|---|---|
| Christopher A. Kroeger | Founder, President, Chief Executive Officer & Director |
| Anatol Kreitzer | Chief Discovery Officer |
| Erin Pennock Foff | Chief Medical Officer |
| James Woodruff Lillie | Chief Scientific Officer |
| Jonathan Gillis | Chief Admin & Acc Officer, PAO, Interim CFO & PFO |
| Karl Deisseroth | Co-Founder & Member of Scientific Advisory Board |
| Karoly Nikolich | Founder & Member of Advisory Board |
| Kristopher L. Hanson | General Counsel & Secretary |
| Robert C. Malenka | Co-Founder & Member of Scientific Advisory Board |
MapLight Therapeutics
| Country | United States |
| IPO Date | Oct 24, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 133 |
| CEO | Christopher A. Kroeger |
Contact Details
800 Chesapeake Drive Redwood City,
California 94063 United States
Stock Details
| Ticker Symbol | MPLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001770069 |
| CUSIP Number | 56565P103 |
| ISIN Number | US56565P1030 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove MPLT